Celgene To Collaborate With VentiRx On TRL8 Receptor Agonist For Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
VentiRx’s immunotherapy approach has created a compound, VTX-2337, offering potential in a variety of cancers and complementary to numerous standard-of-care backbones.